share_log

AbbVie | DEF 14A: Definitive information statements

AbbVie | DEF 14A: Definitive information statements

艾伯維公司 | DEF 14A：股東委託書決議
SEC announcement ·  03/19 04:23
牛牛AI助理已提取核心訊息
AbbVie Inc. (AbbVie) has announced its 2024 Annual Meeting of Stockholders to be held virtually on May 3, 2024. The meeting will invite stockholders to vote on the election of five directors, the ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2024, advisory votes on executive compensation and the frequency of future stockholder advisory votes on executive compensation, and a management proposal to eliminate supermajority voting. Additionally, three stockholder proposals will be considered if properly presented. The meeting will also address any other matters that may properly come before it, including three stockholder proposals if presented. Stockholders as of the record date, March 4, 2024, are entitled to notice of and to vote at the meeting. AbbVie's board recommends voting for the election of the nominated directors, for the ratification of Ernst & Young LLP, for the approval of named executive officers' compensation, for annual advisory approvals of executive compensation, for the management proposal to eliminate supermajority voting, and against each of the stockholder proposals.
AbbVie Inc. (AbbVie) has announced its 2024 Annual Meeting of Stockholders to be held virtually on May 3, 2024. The meeting will invite stockholders to vote on the election of five directors, the ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2024, advisory votes on executive compensation and the frequency of future stockholder advisory votes on executive compensation, and a management proposal to eliminate supermajority voting. Additionally, three stockholder proposals will be considered if properly presented. The meeting will also address any other matters that may properly come before it, including three stockholder proposals if presented. Stockholders as of the record date, March 4, 2024, are entitled to notice of and to vote at the meeting. AbbVie's board recommends voting for the election of the nominated directors, for the ratification of Ernst & Young LLP, for the approval of named executive officers' compensation, for annual advisory approvals of executive compensation, for the management proposal to eliminate supermajority voting, and against each of the stockholder proposals.
艾伯維公司（AbbVie）宣佈其2024年年度股東大會將於2024年5月3日虛擬舉行。會議將邀請股東就五名董事的選舉、批准安永會計師事務所作爲艾伯維2024年獨立註冊會計師事務所、就高管薪酬和未來股東就高管薪酬進行諮詢投票的頻率以及取消絕大多數投票的管理層提案進行投票。此外，如果提交得當，將考慮三份股東提案。會議還將討論可能恰當提出的任何其他問題，包括三份股東提案（如果提出）。截至創紀錄的日期，即2024年3月4日，股東有權獲得會議通知並在會議上投票。艾伯維董事會建議投票選舉提名董事，批准安永會計師事務所，批准指定執行官的薪酬，對高管薪酬的年度諮詢批准，管理層取消絕大多數投票的提議，反對每項股東提案。
艾伯維公司（AbbVie）宣佈其2024年年度股東大會將於2024年5月3日虛擬舉行。會議將邀請股東就五名董事的選舉、批准安永會計師事務所作爲艾伯維2024年獨立註冊會計師事務所、就高管薪酬和未來股東就高管薪酬進行諮詢投票的頻率以及取消絕大多數投票的管理層提案進行投票。此外，如果提交得當，將考慮三份股東提案。會議還將討論可能恰當提出的任何其他問題，包括三份股東提案（如果提出）。截至創紀錄的日期，即2024年3月4日，股東有權獲得會議通知並在會議上投票。艾伯維董事會建議投票選舉提名董事，批准安永會計師事務所，批准指定執行官的薪酬，對高管薪酬的年度諮詢批准，管理層取消絕大多數投票的提議，反對每項股東提案。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。